Omeros (OMER)
(Delayed Data from NSDQ)
$4.87 USD
-0.15 (-2.99%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $4.85 -0.02 (-0.41%) 7:18 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Brokerage Reports
0 items in cart
Omeros Corporation [OMER]
Reports for Purchase
Showing records 41 - 60 ( 423 total )
Company: Omeros Corporation
Industry: Medical - Products
COVID-19 Impact on Elective Surgeries - Read-Through to Our Select Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Q4/FY19; Positive Topline For Pivotal Narsoplimab/HSCTTMA Trial
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
2019 Financial Results Reported; Narsoplimab Filing Completion Nears; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Narsoplimab Disclosure Strategy Limits Upside Until Approval In Our View
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
OMIDRIA Pricing Outlook; 3Q19 Financials; Adjusting Target to $34
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Q3 Financials; BLA Submission for Narsoplimab/HSCT-TMA Anticipated in H1:20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Recent Downside Action Appears Unwarranted; OMIDRIA Pass-Through Status Extension Still Possible
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
OMIDRIA Reduced Fentanyl Use; Pass-Through Reimbursement Implications
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Multiple Recent Regulatory Advances for Narsoplimab; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Narsoplimab/HSCT-TMA Receives Positive Opinion from EMA PDCO for PIP
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Initiation of Rolling BLA for Narsoplimab for the Treatment of HSCT-TMA
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
OMIDRIA Product-Specific J-Code Takes Effect; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Positive OMS527 Phase 1 Data Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Safety and Tolerability Demonstrated in OMS527 Phase 1 Study for Addiction
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Narsoplimab Regulatory Submission Pathway Confirmed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
GPR174 Involvement in Immuno-Oncology Revealed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R